Guillermina Lozano

List of Publications by Year
in descending order

134	13,461	20817 60	21540 114
papers	citations	h-index	g-index

136	136	136	14794
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Alterations of the Mdm2 C-Terminus Differentially Impact Its Function <i>In Vivo</i>. Cancer Research, 2022, 82, 1313-1320.	0.9	2
2	Differential Gain-of-Function Activity of Three p53 Hotspot Mutants <i>In Vivo</i>. Cancer Research, 2022, 82, 1926-1936.	0.9	14
3	Is loss of p53 a driver of ductal carcinoma in situ progression?. British Journal of Cancer, 2022, 127, 1744-1754.	6.4	1
4	The Common Germline <i>TP53-R337H</i> Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Research, 2021, 81, 2442-2456.	0.9	9
5	Oncogenic <i>KRAS</i> Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discovery, 2021, 11, 2094-2111.	9.4	66
6	MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell, 2021, 39, 529-547.e7.	16.8	17
7	Wnt/ÃŸ-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells. Cell Death and Disease, 2021, 12, 521.	6.3	12
8	A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4969-e4980.	3.6	9
9	Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study. JMIR Cancer, 2021, 7, e25621.	2.4	2
10	Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nature Communications, 2021, 12, 5389.	12.8	14
11	p53 tetramerization: at the center of the dominant-negative effect of mutant p53. Genes and Development, 2020, 34, 1128-1146.	5.9	54
12	p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23663-23673.	7.1	26
13	Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. Science Advances, 2020, 6, eaba8415.	10.3	22
14	Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6622-6629.	7.1	13
15	Transient enhancement of p53 activity protects from radiation-induced gastrointestinal toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17429-17437.	7.1	18
16	Restoring p53 in cancer: the promises and the challenges. Journal of Molecular Cell Biology, 2019, 11, 615-619.	3.3	21
17	Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence. Neuro-Oncology Advances, 2019, 1, vdz027.	0.7	5
18	Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. Cancer Research, 2019, 79, 2662-2668.	0.9	10

#	Article	IF	Citations
19	Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nature Communications, 2019, 10, 5385.	12.8	53
20	Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 960-969.	7.1	13
21	SNPing away at mutant p53 activities. Genes and Development, 2018, 32, 195-196.	5.9	5
22	Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2198-2203.	7.1	9
23	Mutant p53 partners in crime. Cell Death and Differentiation, 2018, 25, 161-168.	11.2	216
24	Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology, 2018, 155, 210-223.e3.	1.3	114
25	One step at a time. Molecular Biology of the Cell, 2018, 29, 2614-2615.	2.1	0
26	Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nature Communications, 2018, 9, 3953.	12.8	45
27	CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo. Cell Death and Disease, 2018, 9, 1099.	6.3	50
28	Daxx Functions Are p53-Independent <i>In Vivo</i>. Molecular Cancer Research, 2018, 16, 1523-1529.	3.4	12
29	A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53. PLoS ONE, 2018, 13, e0193485.	2.5	8
30	Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. Journal of the National Cancer Institute, 2017, 109, .	6.3	19
31	The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. Journal of Pathology, 2017, 241, 501-510.	4.5	27
32	Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein. Genes and Development, 2017, 31, 1847-1857.	5.9	48
33	The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026112.	6.2	42
34	p53: Multiple Facets of a Rubik's Cube. Annual Review of Cancer Biology, 2017, 1, 185-201.	4.5	18
35	Mdm proteins: critical regulators of embryogenesis and homoeostasis. Journal of Molecular Cell Biology, 2017, 9, 16-25.	3.3	26
36	TNBC invasion: downstream of STAT3. Oncotarget, 2017, 8, 20517-20518.	1.8	5

#	Article	IF	Citations
37	Tumorigenesis promotes Mdm4-S overexpression. Oncotarget, 2017, 8, 25837-25847.	1.8	8
38	Loss of digestive organ expansion factor (<i>Diexf)</i> reveals an essential role during murine embryonic development that is independent of p53. Oncotarget, 2017, 8, 103996-104006.	1.8	7
39	The Enigma of p53. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 37-40.	1.1	10
40	Mutant p53 in concert with an interleukinâ€27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology, 2016, 63, 1000-1012.	7.3	29
41	Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026211.	6.2	105
42	p53 Activity Dominates That of p73 upon <i>Mdm4</i> Loss in Development and Tumorigenesis. Molecular Cancer Research, 2016, 14, 56-65.	3.4	6
43	Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 <i>In Vivo</i>. Clinical Cancer Research, 2016, 22, 3876-3883.	7.0	15
44	Novel <i>MYBL1</i> Gene Rearrangements with Recurrent <i>MYBL1â€"NFIB</i> Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clinical Cancer Research, 2016, 22, 725-733.	7.0	167
45	MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Molecular Cell, 2016, 61, 68-83.	9.7	82
46	Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer. Frontiers in Oncology, 2015, 5, 249.	2.8	80
47	TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. Journal of Hepatology, 2015, 62, 371-379.	3.7	63
48	Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget, 2015, 6, 17968-17980.	1.8	21
49	Tissueâ€specific and ageâ€dependent effects of global Mdm2 loss. Journal of Pathology, 2014, 233, 380-391.	4.5	33
50	Loss of the novel tumour suppressor and polarity gene <i>Trim62</i> (<i>Dear1</i>) synergizes with oncogenic Ras in invasive lung cancer. Journal of Pathology, 2014, 234, 108-119.	4.5	21
51	Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11145-11150.	7.1	77
52	The Mdm Network and Its Regulation of p53 Activities: A Rheostat of Cancer Risk. Human Mutation, 2014, 35, 728-737.	2.5	67
53	USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nature Immunology, 2014, 15, 562-570.	14.5	204
54	Therapeutic Efficacy of <i>p53</i> Restoration in <i>Mdm2</i>-Overexpressing Tumors. Molecular Cancer Research, 2014, 12, 901-911.	3.4	27

#	Article	IF	Citations
55	Limiting the power of p53 through the ubiquitin proteasome pathway. Genes and Development, 2014, 28, 1739-1751.	5.9	131
56	Inhibition of Endothelial p53 Improves Metabolic Abnormalities Related to Dietary Obesity. Cell Reports, 2014, 7, 1691-1703.	6.4	95
57	Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. Oncotarget, 2014, 5, 1149-1156.	1.8	23
58	Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy. Clinical Cancer Research, 2013, 19, 34-41.	7.0	161
59	Mutant p53-Driven Tumorigenesis. , 2013, , 77-93.		0
60	Mutant p53 Prolongs NF-ÎºB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer. Cancer Cell, 2013, 23, 634-646.	16.8	388
61	Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle, 2013, 12, 1722-1731.	2.6	25
62	The p53â€“Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes and Development, 2013, 27, 1857-1867.	5.9	62
63	<i>DEAR1</i> Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-Î²â€“Driven Epithelialâ€“Mesenchymal Transition. Cancer Discovery, 2013, 3, 1172-1189.	9.4	40
64	BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The EÎ¼-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status. Blood, 2013, 122, 876-876.	1.4	0
65	The Many Faces of MDM2 Binding Partners. Genes and Cancer, 2012, 3, 226-239.	1.9	51
66	p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer. Cancer Cell, 2012, 21, 793-806.	16.8	279
67	Developing Genetically Engineered Mouse Models to Study Tumor Suppression. Current Protocols in Mouse Biology, 2012, 2, 9-24.	1.2	0
68	Regulation of tissueâ€•and stimulusâ€•specific cell fate decisions by <i>p53 in vivo</i>. Journal of Pathology, 2011, 223, 127-137.	4.5	49
69	Multiple Stress Signals Activate Mutant p53 <i>In Vivo</i>. Cancer Research, 2011, 71, 7168-7175.	0.9	104
70	Mutant p53 Disrupts Role of ShcA Protein in Balancing Smad Protein-dependent and -independent Signaling Activity of Transforming Growth Factor-Î² (TGF-Î²)*. Journal of Biological Chemistry, 2011, 286, 44023-44034.	3.4	10
71	The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle, 2011, 10, 3257-3262.	2.6	27
72	Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11995-12000.	7.1	124

#	Article	IF	Citations
73	Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. Journal of Clinical Investigation, 2011, 121, 893-904.	8.2	113
74	p53-Mediated Stress and Tissue-Dependent Cell Fate Decisions; Implications for p53 Targeting. Blood, 2011, 118, SCI-3-SCI-3.	1.4	0
75	A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development. Cancer Cell, 2010, 18, 220-230.	16.8	108
76	You can win by losing: p53 mutations in rhabdomyosarcomas. Journal of Pathology, 2010, 222, 124-128.	4.5	2
77	Mouse Models of p53 Functions. Cold Spring Harbor Perspectives in Biology, 2010, 2, a001115-a001115.	5.5	85
78	Spontaneous Tumorigenesis in Mice Overexpressing the p53-Negative Regulator Mdm4. Cancer Research, 2010, 70, 7148-7154.	0.9	70
79	Mdm2 Is Required for Survival of Hematopoietic Stem Cells/Progenitors via Dampening of ROS-Induced p53 Activity. Cell Stem Cell, 2010, 7, 606-617.	11.1	126
80	Regulation of p53 Activity and Associated Checkpoint Controls. , 2010, , 171-188.		2
81	Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma. PLoS ONE, 2009, 4, e5401.	2.5	65
82	20 years studying p53 functions in genetically engineered mice. Nature Reviews Cancer, 2009, 9, 831-841.	28.4	193
83	Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation, 2009, 77, 442-449.	1.9	27
84	<i>Mdm2</i> and <i>Mdm4</i> Loss Regulates Distinct p53 Activities. Molecular Cancer Research, 2008, 6, 947-954.	3.4	86
85	The inherent instability of mutant p53 is alleviated by <i>Mdm2</i> or <i>p16^{INK4a}</i> loss. Genes and Development, 2008, 22, 1337-1344.	5.9	317
86	p53 Plays a Role in Mesenchymal Differentiation Programs, in a Cell Fate Dependent Manner. PLoS ONE, 2008, 3, e3707.	2.5	146
87	New mouse models of cancer: Single-cell knockouts. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4245-4246.	7.1	10
88	Loss of Mdm4 Results in p53 -Dependent Dilated Cardiomyopathy. Circulation, 2007, 115, 2925-2930.	1.6	63
89	Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development. Molecular and Cellular Biology, 2007, 27, 5479-5485.	2.3	102
90	Distinct roles of Mdm2 and Mdm4 in red cell production. Blood, 2007, 109, 2630-2633.	1.4	63

#	Article	IF	Citations
91	The oncogenic roles of p53 mutants in mouse models. Current Opinion in Genetics and Development, 2007, 17, 66-70.	3.3	79
92	High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Human Pathology, 2007, 38, 1553-1562.	2.0	78
93	Telomere dysfunction suppresses spontaneous tumorigenesis <i>in vivo</i> by initiating p53â€dependent cellular senescence. EMBO Reports, 2007, 8, 497-503.	4.5	185
94	HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Modern Pathology, 2007, 20, 54-62.	5.5	37
95	Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mammalian Genome, 2007, 18, 300-309.	2.2	39
96	An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. Journal of Clinical Investigation, 2007, 117, 1893-1901.	8.2	122
97	Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor. , 2007, , 183-207.		0
98	Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor. , 2007, , 183-207.		0
99	Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3226-3231.	7.1	138
100	p21 delays tumor onset by preservation of chromosomal stability. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19842-19847.	7.1	97
101	Tissue-Specific Differences of p53 Inhibition by Mdm2 and Mdm4. Molecular and Cellular Biology, 2006, 26, 192-198.	2.3	131
102	p21 stability: Linking chaperones to a cell cycle checkpoint. Cancer Cell, 2005, 7, 113-114.	16.8	65
103	Gankyrin: An intriguing name for a novel regulator of p53 and RB. Cancer Cell, 2005, 8, 3-4.	16.8	50
104	What have animal models taught us about the p53 pathway?. Journal of Pathology, 2005, 205, 206-220.	4.5	69
105	Increased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389. Molecular and Cellular Biology, 2004, 24, 8884-8894.	2.3	116
106	Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genetics, 2004, 36, 63-68.	21.4	306
107	Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene, 2004, 23, 7644-7650.	5.9	18
108	Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome. Cell, 2004, 119, 861-872.	28.9	930

#	Article	IF	Citations
109	A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. Cell, 2004, 119, 591-602.	28.9	1,158
110	Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Human Genetics, 2003, 113, 238-243.	3.8	94
111	DisruptingTP53 in mouse models of human cancers. Human Mutation, 2003, 21, 321-326.	2.5	43
112	Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation. Cell, 2003, 112, 779-791.	28.9	657
113	Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Research, 2003, 63, 8664-9.	0.9	63
114	MDM2, an introduction. Molecular Cancer Research, 2003, 1, 993-1000.	3.4	321
115	Conditional allele ofmdm2 which encodes a p53 inhibitor. Genesis, 2002, 32, 145-147.	1.6	44
116	A DNA Damageâ€"Induced p53 Serine 392 Kinase Complex Contains CK2, hSpt16, and SSRP1. Molecular Cell, 2001, 7, 283-292.	9.7	271
117	Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genetics, 2001, 29, 92-95.	21.4	456
118	An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene, 2001, 20, 4041-4049.	5.9	126
119	Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene, 2000, 19, 358-364.	5.9	81
120	The loss of mdm2 induces p53 mediated apoptosis. Oncogene, 2000, 19, 1691-1697.	5.9	116
121	p53 sends nucleotides to repair DNA. Nature, 2000, 404, 24-25.	27.8	112
122	p53-independent functions of the p19ARF tumor suppressor. Genes and Development, 2000, 14, 2358-2365.	5.9	317
123	TP53 mutation and haplotype analysis of two large African American families. , 1999, 14, 216-221.		7
124	Loss of one but not twomdm2 null alleles alters the tumour spectrum inp53 null mice. , 1999, 188, 322-328.		41
125	Mouse models dissect the role of p53 in cancer and development. Seminars in Cancer Biology, 1998, 8, 337-344.	9.6	38
126	The cenpB gene is not essential in mice. Chromosoma, 1998, 107, 570-576.	2.2	131

#	Article	IF	Citations
127	Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Human Genetics, 1998, 102, 681-686.	3.8	30
128	The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene, 1997, 15, 1527-1534.	5.9	64
129	Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene, 1997, 15, 2767-2772.	5.9	86
130	Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nature Genetics, 1997, 16, 336-337.	21.4	16
131	The Li-Fraumeni syndrome: An inherited susceptibility to cancer. Trends in Molecular Medicine, 1997, 3, 390-395.	2.6	80
132	The Organization and Expression of themdm2Gene. Genomics, 1996, 33, 352-357.	2.9	42
133	Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 1995, 378, 203-206.	27.8	1,338
134	Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Molecular Carcinogenesis, 1991, 4, 3-9.	2.7	75